Genprex, Inc. GNPX
Genprex, Inc. (Nasdaq: GNPX) is an oncology drug developer. Its lead program, REQORSA (quaratusugene ozeplasmid; GPX-001), is in Phase 2 for Non-small cell lung cancer (EGFR-mutant, post-Tagrisso) and extensive-stage small cell lung cancer. Its next catalyst on record is REQORSA (Acclaim-3): Complete enrollment of first 25 patients for interim analysis (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: REQORSA (Acclaim-3) — Complete enrollment of first 25 patients for interim analysis (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| REQORSA + Tagrisso (Acclaim-1) | Late-stage EGFR-mutant NSCLC progressed on Tagrisso | gene therapy | Phase 2 |
| REQORSA + Tecentriq (Acclaim-3) | Extensive-stage small cell lung cancer (maintenance) | gene therapy | Phase 2 |
| GPX-002 (AAV Pdx1/MafA) | Type 1 and Type 2 diabetes | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.